{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:03:37Z","timestamp":1781831017229,"version":"3.54.5"},"reference-count":87,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Diseases caused by human herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) affect millions of people worldwide and range from fatal encephalitis in neonates and herpes keratitis to orofacial and genital herpes, among other manifestations. The viruses can be shed efficiently by asymptomatic carriers, causing increased rates of infection. Viral transmission occurs through direct contact of mucosal surfaces followed by initial replication of the incoming virus in skin tissues. Subsequently, the viruses infect sensory neurons in the trigeminal and lumbosacral dorsal root ganglia, where they are primarily maintained in a transcriptionally repressed state termed \u201clatency\u201d, which persists for the lifetime of the host. HSV DNA has also been detected in other sympathetic ganglia. Periodically, latent viruses can reactivate, causing ulcerative and often painful lesions primarily at the site of primary infection and proximal sites. In the United States, recurrent genital herpes alone accounts for more than a billion dollars in direct medical costs per year, while there are much higher costs associated with the socio-economic aspects of diseased patients, such as loss of productivity due to mental anguish. Currently, there are no effective FDA-approved vaccines for either prophylactic or therapeutic treatment of human herpes simplex infections, while several recent clinical trials have failed to achieve their endpoint goals. Historically, live-attenuated vaccines have successfully combated viral diseases, including polio, influenza, measles, and smallpox. Vaccines aimed to protect against the devastation of smallpox led to the most significant achievement in medical history: the eradication of human disease by vaccination. Recently, novel approaches toward developing safe and effective live-attenuated vaccines have demonstrated high efficacy in various preclinical models of herpetic disease. This next generation of live-attenuated vaccines has been tailored to minimize vaccine-associated side effects and promote effective and long-lasting immune responses. The ultimate goal is to prevent or reduce primary infections (prophylactic vaccines) or reduce the frequency and severity of disease associated with reactivation events (therapeutic vaccines). These vaccines\u2019 \u201crational\u201d design is based on our current understanding of the immunopathogenesis of herpesviral infections that guide the development of vaccines that generate robust and protective immune responses. This review covers recent advances in the development of herpes simplex vaccines and the current state of ongoing clinical trials in pursuit of an effective vaccine against herpes simplex virus infections and associated diseases.<\/jats:p>","DOI":"10.3390\/v13081637","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T22:51:00Z","timestamp":1629327060000},"page":"1637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses"],"prefix":"10.3390","volume":"13","author":[{"given":"Brent A.","family":"Stanfield","sequence":"first","affiliation":[{"name":"Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin G.","family":"Kousoulas","sequence":"additional","affiliation":[{"name":"Division of Biotechnology and Molecular Medicine, Louisiana State University, Baton Rouge, LA 70803, USA"},{"name":"Rational Vaccines Inc., Woburn, MA 01801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Rational Vaccines Inc., Woburn, MA 01801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gershburg","sequence":"additional","affiliation":[{"name":"Rational Vaccines Inc., Woburn, MA 01801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: Global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Looker, K.J., Magaret, A.S., May, M.T., Turner, K.M.E., Vickerman, P., Gottlieb, S.L., and Newman, L.M. (2015). Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140765"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Looker, K.J., Magaret, A.S., Turner, K.M., Vickerman, P., Gottlieb, S.L., and Newman, L.M. (2015). Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128615"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/sextrans-2018-053830","article-title":"Increasing proportion of herpes simplex virus type 1 among women and men diagnosed with first-episode anogenital herpes: A retrospective observational study over 14 years in Melbourne, Australia","volume":"95","author":"Durukan","year":"2018","journal-title":"Sex. Transm. Infect."},{"key":"ref_5","first-page":"53","article-title":"Genital Infection With Herpes Simplex Virus Type 1 and Type 2 in Valencia, Spain: A Retrospective Observational Study","volume":"111","year":"2019","journal-title":"Actas Dermosifiliogr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/OLQ.0000000000001375","article-title":"Estimates of the Prevalence and Incidence of Genital Herpes, United States, 2018","volume":"48","author":"Spicknall","year":"2021","journal-title":"Sex. Transm. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40588-015-0020-4","article-title":"Herpes Simplex Vaccines: Prospects of Live-Attenuated HSV Vaccines to Combat Genital and Ocular Infections","volume":"2","author":"Stanfield","year":"2015","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ayoub, H.H., Chemaitelly, H., and Abu-Raddad, L.J. (2020). Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses. Vaccines, 8.","DOI":"10.3390\/vaccines8030366"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21775\/cimb.041.469","article-title":"Alphaherpesvirus Vaccines","volume":"41","author":"Aschner","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/vim.2016.0136","article-title":"An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model","volume":"30","author":"Bagley","year":"2017","journal-title":"Viral Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eaaw7083","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Atukorale, V.N., Weir, J.P., and Meseda, C.A. (2020). Stability of the HSV-2 US-6 Gene in the del II, del III, CP77, and I8R-G1L Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells. Vaccines, 8.","DOI":"10.3390\/vaccines8010137"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00535-18","DOI":"10.1128\/JVI.00535-18","article-title":"Human Asymptomatic Epitope Peptide\/CXCL10-Based Prime\/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107 + CD8 + T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge","volume":"92","author":"Khan","year":"2018","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1016\/j.vaccine.2019.08.077","article-title":"Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e02163-19","DOI":"10.1128\/JVI.02163-19","article-title":"Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity","volume":"94","author":"Patel","year":"2020","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00616-18","DOI":"10.1128\/JVI.00616-18","article-title":"Immunization by Replication-Competent Controlled Herpesvirus Vectors","volume":"92","author":"Bloom","year":"2018","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eaau6039","DOI":"10.1126\/scitranslmed.aau6039","article-title":"Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity","volume":"11","author":"Patel","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41385-019-0131-y","article-title":"Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection","volume":"12","author":"Royer","year":"2019","journal-title":"Mucosal Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bernstein, D.I., Cardin, R.D., Pullum, D.A., Bravo, F.J., Kousoulas, K.G., and Dixon, D.A. (2019). Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213401"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-020-00254-8","article-title":"The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model","volume":"5","author":"Bernstein","year":"2020","journal-title":"Npj Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Naidu, S.K., Nabi, R., Cheemarla, N., Stanfield, B., Rider, P.J., Jambunathan, N., Chouljenko, V.N., Carter, R., Del Piero, F., and Langohr, I. (2020). Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228252"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1086\/514103","article-title":"Immunotherapy of Recurrent Genital Herpes with Recombinant Herpes Simplex Virus Type 2 Glycoproteins D and B: Results of a Placebo-Controlled Vaccine Trial","volume":"176","author":"Straus","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV Vaccine Study Group","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11990","DOI":"10.1128\/JVI.79.18.11990-12001.2005","article-title":"The Extracellular Domain of Herpes Simplex Virus gE Is Indispensable for Efficient Cell-to-Cell Spread: Evidence for gE\/gI Receptors","volume":"79","author":"Polcicova","year":"2005","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.01130-14","article-title":"Blocking Herpes Simplex Virus 2 Glycoprotein E Immune Evasion as an Approach To Enhance Efficacy of a Trivalent Subunit Antigen Vaccine for Genital Herpes","volume":"88","author":"Awasthi","year":"2014","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41541-019-0129-1","article-title":"Successful application of prime and pull strategy for a therapeutic HSV vaccine","volume":"4","author":"Bernstein","year":"2019","journal-title":"Npj Vaccines"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41467-020-15992-5","article-title":"Integrative functional genomics decodes herpes simplex virus 1","volume":"11","author":"Whisnant","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10787-021-00811-0","article-title":"Brief review of the mRNA vaccines COVID-19","volume":"29","author":"Vitiello","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_29","first-page":"712","article-title":"Coronavirus Variants-Will New mRNA Vaccines Meet the Challenge?","volume":"7","author":"Welsh","year":"2021","journal-title":"Engineering (Beijing)"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: The development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr. Drug Targets Infect Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/ITT.S176383","article-title":"Varicella zoster virus vaccines: An update","volume":"8","author":"Gabutti","year":"2019","journal-title":"ImmunoTargets Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Glorioso, J.C., Cohen, J.B., Goins, W.F., Hall, B., Jackson, J.W., Kohanbash, G., Amankulor, N., Kaur, B., Caligiuri, M.A., and Chiocca, E.A. (2020). Oncolytic HSV Vectors and Anti-Tumor Immunity, Caister Academic Press.","DOI":"10.21775\/9781913652555.11"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1128\/JVI.72.3.2010-2021.1998","article-title":"The genome sequence of herpes simplex virus type 2","volume":"72","author":"Dolan","year":"1998","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.vaccine.2021.03.075","article-title":"Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0DeltaNLS vaccine against ocular HSV-1 challenge","volume":"39","author":"Carr","year":"2021","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4049\/immunohorizons.2000060","article-title":"Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1\u2013Encoded Proteins","volume":"4","author":"Carr","year":"2020","journal-title":"ImmunoHorizons"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Richards, A.L., Sollars, P.J., Pitts, J.D., Stults, A.M., Heldwein, E.E., Pickard, G.E., and Smith, G.A. (2017). The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion. PLOS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006741"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vaccine.2018.11.042","article-title":"The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2018","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1128\/JVI.00147-08","article-title":"Functional and Physical Interactions of the Herpes Simplex Virus Type 1 UL20 Membrane Protein with Glycoprotein K","volume":"82","author":"Foster","year":"2008","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1128\/JVI.78.10.5347-5357.2004","article-title":"The Herpes Simplex Virus Type 1 UL20 Protein Modulates Membrane Fusion Events during Cytoplasmic Virion Morphogenesis and Virus-Induced Cell Fusion","volume":"78","author":"Foster","year":"2004","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12301","DOI":"10.1128\/JVI.01329-09","article-title":"The amino terminus of herpes simplex virus type 1 glycoprotein K (gK) modulates gB-mediated virus-induced cell fusion and virion egress","volume":"83","author":"Chouljenko","year":"2009","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.1128\/JVI.00298-10","article-title":"The Herpes Simplex Virus Type 1 UL20 Protein and the Amino Terminus of Glycoprotein K (gK) Physically Interact with gB","volume":"84","author":"Chouljenko","year":"2010","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1128\/jvi.66.9.5603-5609.1992","article-title":"Identification and characterization of a novel herpes simplex virus glycoprotein, gK, involved in cell fusion","volume":"66","author":"Hutchinson","year":"1992","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/JVI.79.1.299-313.2005","article-title":"Herpes Simplex Virus Type 1 gK Is Required for gB-Mediated Virus-Induced Cell Fusion, While neither gB and gK nor gB and UL20p Function Redundantly in Virion De-Envelopment","volume":"79","author":"Melancon","year":"2005","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1128\/JVI.02468-15","article-title":"Deletion of a Predicted beta-Sheet Domain within the Amino Terminus of Herpes Simplex Virus Glycoprotein K Conserved among Alphaherpesviruses Prevents Virus Entry into Neuronal Axons","volume":"90","author":"Jambunathan","year":"2015","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14625","DOI":"10.1038\/s41598-019-50490-9","article-title":"Identification and Visualization of Functionally Important Domains and Residues in Herpes Simplex Virus Glycoprotein K(gK) Using a Combination of Phylogenetics and Protein Modeling","volume":"9","author":"Rider","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e00873-17","DOI":"10.1128\/JVI.00873-17","article-title":"Cysteines and N-Glycosylation Sites Conserved among All Alphaherpesviruses Regulate Membrane Fusion in Herpes Simplex Virus 1 Infection","volume":"91","author":"Rider","year":"2017","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e01842-17","DOI":"10.1128\/JVI.01842-17","article-title":"The Amino Terminus of Herpes Simplex Virus 1 Glycoprotein K (gK) Is Required for gB Binding to Akt, Release of Intracellular Calcium, and Fusion of the Viral Envelope with Plasma Membranes","volume":"92","author":"Musarrat","year":"2018","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/v4050800","article-title":"Herpes Virus Fusion and Entry: A Story with Many Characters","volume":"4","author":"Eisenberg","year":"2012","journal-title":"Viruses"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e01268-17","DOI":"10.1128\/mBio.01268-17","article-title":"The Fusion Loops of the Initial Prefusion Conformation of Herpes Simplex Virus 1 Fusion Protein Point Toward the Membrane","volume":"8","author":"Fontana","year":"2017","journal-title":"mBio"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coviro.2017.04.006","article-title":"The COMPLEXity in herpesvirus entry","volume":"24","author":"Sathiyamoorthy","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-319-53168-7_2","article-title":"Herpes simplex virus Membrane Fusion","volume":"223","author":"Weed","year":"2017","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gianni, T., Salvioli, S., Chesnokova, L.S., Hutt-Fletcher, L.M., and Campadelli-Fiume, G. (2013). alphavbeta6- and alphavbeta8-integrins serve as interchangeable receptors for HSV gH\/gL to promote endocytosis and activation of membrane fusion. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003806"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/tra.12408","article-title":"Herpesvirus Entry into Host Cells Mediated by Endosomal Low pH","volume":"17","author":"Nicola","year":"2016","journal-title":"Traffic"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-981-10-7230-7_1","article-title":"The Role of HSV Glycoproteins in Mediating Cell Entry","volume":"1045","author":"Arii","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1128\/JVI.02982-12","article-title":"The Amino Terminus of Herpes Simplex Virus 1 Glycoprotein K Is Required for Virion Entry via the Paired Immunoglobulin-Like Type-2 Receptor Alpha","volume":"87","author":"Chowdhury","year":"2013","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3389\/fcimb.2020.617578","article-title":"Herpes Simplex Virus Cell Entry Mechanisms: An Update","volume":"10","author":"Madavaraju","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/fvl.11.24","article-title":"HSV-1 ICP0: Paving the way for viral replication","volume":"6","author":"Smith","year":"2011","journal-title":"Future Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1128\/jvi.66.5.2904-2915.1992","article-title":"Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells","volume":"66","author":"Cai","year":"1992","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1128\/jvi.63.11.4579-4589.1989","article-title":"Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA","volume":"63","author":"Cai","year":"1989","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1099\/0022-1317-70-5-1185","article-title":"Construction and Characterization of Herpes Simplex Virus Type 1 Mutants with Defined Lesions in Immediate Early Gene 1","volume":"70","author":"Everett","year":"1989","journal-title":"J. Gen. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1128\/jvi.61.3.829-839.1987","article-title":"Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture","volume":"61","author":"Sacks","year":"1987","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1099\/0022-1317-67-12-2571","article-title":"Isolation and Characterization of a Herpes Simplex Virus Type 1 Mutant Containing a Deletion within the Gene Encoding the Immediate Early Polypeptide Vmw110","volume":"67","author":"Stow","year":"1986","journal-title":"J. Gen. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1128\/jvi.67.12.7501-7512.1993","article-title":"The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency","volume":"67","author":"Cai","year":"1993","journal-title":"J Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1128\/JVI.74.13.5957-5967.2000","article-title":"Optimized Viral Dose and Transient Immunosuppression Enable Herpes Simplex Virus ICP0-Null Mutants To Establish Wild-Type Levels of Latency In Vivo","volume":"74","author":"Halford","year":"2000","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1128\/JVI.75.7.3240-3249.2001","article-title":"ICP0 Is Required for Efficient Reactivation of Herpes Simplex Virus Type 1 from Neuronal Latency","volume":"75","author":"Halford","year":"2001","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/jvi.63.2.759-768.1989","article-title":"Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency","volume":"63","author":"Leib","year":"1989","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/j.1460-2075.1984.tb02270.x","article-title":"Trans activation of transcription by herpes virus products: Requirement for two HSV-1 immediate-early polypeptides for maximum activity","volume":"3","author":"Everett","year":"1984","journal-title":"EMBO J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1073\/pnas.82.16.5265","article-title":"Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene","volume":"82","author":"Gelman","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1128\/jvi.56.3.723-733.1985","article-title":"Three trans-acting regulatory proteins of herpes simplex virus modulate immediate-early gene expression in a pathway involving positive and negative feedback regulation","volume":"56","author":"Hayward","year":"1985","journal-title":"J. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1099\/0022-1317-67-11-2365","article-title":"Characterization of the IE110 Gene of Herpes Simplex Virus Type 1","volume":"67","author":"Perry","year":"1986","journal-title":"J. Gen. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41564-020-00826-3","article-title":"Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription","volume":"6","author":"Kim","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Reddi, T.S., Merkl, P.E., Lim, S.-Y., Letvin, N.L., and Knipe, D.M. (2021). Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009281"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11209","DOI":"10.1128\/JVI.01145-12","article-title":"Herpes Simplex Virus 1 Ubiquitin Ligase ICP0 Interacts with PML Isoform I and Induces Its SUMO-Independent Degradation","volume":"86","author":"Vanni","year":"2012","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ansari, M.A., Dutta, S., Veettil, M.V., Dutta, D., Iqbal, J., Kumar, B., Roy, A., Chikoti, L., Singh, V.V., and Chandran, B. (2015). Herpesvirus Genome Recognition Induced Acetylation of Nuclear IFI16 Is Essential for Its Cytoplasmic Translocation, Inflammasome and IFN-beta Responses. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005019"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1073\/pnas.1203447109","article-title":"Acetylation modulates cellular distribution and DNA sensing ability of interferon-inducible protein IFI16","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"13422","DOI":"10.1128\/JVI.02474-13","article-title":"The viral ubiquitin ligase ICP0 is neither sufficient nor necessary for degradation of the cellular DNA sensor IFI16 during herpes simplex virus 1 infection","volume":"87","author":"Anderson","year":"2013","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1128\/JVI.00082-13","article-title":"Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes","volume":"87","author":"Johnson","year":"2013","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"E3008","DOI":"10.1073\/pnas.1211302109","article-title":"Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein","volume":"109","author":"Orzalli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"22216","DOI":"10.1038\/s41598-020-77725-4","article-title":"Herpes simplex virus 1 targets IRF7 via ICP0 to limit type I IFN induction","volume":"10","author":"Shahnazaryan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"12935","DOI":"10.1128\/JVI.01952-13","article-title":"Herpes simplex virus 1 E3 ubiquitin ligase ICP0 protein inhibits tumor necrosis factor alpha-induced NF-kappaB activation by interacting with p65\/RelA and p50\/NF-kappaB1","volume":"87","author":"Zhang","year":"2013","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1128\/JVI.02327-06","article-title":"Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome","volume":"81","author":"Kummer","year":"2007","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Halford, W.P., Puschel, R., Gershburg, E., Wilber, A., Gershburg, S., and Rakowski, B. (2011). A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017748"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Halford, W.P., Geltz, J., and Gershburg, E. (2013). Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065523"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Geltz, J.J., Gershburg, E., and Halford, W.P. (2015). Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116091"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e03552-20","DOI":"10.1128\/mBio.03552-20","article-title":"Herpes Simplex Virus 1 Manipulates Host Cell Antiviral and Proviral DNA Damage Responses","volume":"12","author":"Mertens","year":"2021","journal-title":"mBio"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5640960","DOI":"10.1155\/2020\/5640960","article-title":"Frequent Recurrences of Genital Herpes Are Associated with Enhanced Systemic HSV-Specific T Cell Response","volume":"2020","author":"Holub","year":"2020","journal-title":"Can. J. Infect. Dis. Med. Microbiol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:46:46Z","timestamp":1760165206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":87,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081637"],"URL":"https:\/\/doi.org\/10.3390\/v13081637","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]}}}